Pasireotid
|
|
|
| Klinički podaci
|
| AHFS/Drugs.com
|
Monografija
|
| Identifikatori
|
| CAS broj
|
396091-73-9
|
| ATC kod
|
H01CB05
|
| PubChem[1][2]
|
9941444
|
| DrugBank
|
DB06663
|
| ChEBI
|
CHEBI:72312  Y
|
| Hemijski podaci
|
| Formula
|
C58H66N10O9
|
| Mol. masa
|
1107,26
|
| SMILES
|
eMolekuli & PubHem
|
| InChI |
|---|
InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1
Key: VMZMNAABQBOLAK-DBILLSOUSA-N Y |
|
| Farmakokinetički podaci
|
| Poluvreme eliminacije
|
12 h,
|
| Farmakoinformacioni podaci
|
| Trudnoća
|
?
|
| Pravni status
|
|
| Način primene
|
Subkutano
|
Pasireotid (SOM230, Signifor[3]) je orfanski lek koji je odobren u SAD i Evropi za lečenje Kušingove bolesti kod pacijenata kod kojih je hiruški zahvat neuspešan ili neprimenljiv.[4][5] Ovaj lek je razvilo preduzeće Novartis. Pasireotid je somatostatinski analog sa 40-puta većim afinitetom za somatostatinski receptor 5 nego za druge analoge somatostatinskog receptora.[6][7][8]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Signifor (pasireotide) Official Website for healthcare professionals outside the US http://www.signifor.com/
- ↑ „Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease”. Pristupljeno 8. 7. 2012.
- ↑ Mancini et al. Therapeutics and Clinical Risk Management 2010;6:505-516
- ↑ Weckbecker G, Briner U, Lewis I, Bruns C: SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002 Oct;143(10):4123-30. PMID 12239124
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. edit
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. edit
